A negative correlation between EZH2 and PD-L1 expression was observed in hepatocellular carcinoma and prostate cancer, which may result from the upregulation of H3K27me3 levels in the promoters of CD274 and IRF1 (66, 68). This evidence concerns the gene EZH2 and prostate carcinoma.